Background: Excessive immune‐mediated inflammatory reactions play a deleterious role in postinfarction ventricular remodeling. Interleukin‐37 ( IL ‐37) emerges as an inhibitor of both innate and adaptive immunity. However, the exact role of IL ‐37 and IL ‐37 plus troponin I (TnI)–treated dendritic cells ( DC s) in ventricular remodeling after myocardial infarction ( MI ) remains elusive. Methods and Results: MI was induced by permanent ligation of the left anterior descending artery. Our results showed that treatment with recombinant human IL ‐37 significantly ameliorated ventricular remodeling after MI , as demonstrated by decreased infarct size, better cardiac function, lower mortality, restricted inflammatory responses, decreased myocardial fibrosis, and inhibited cardiomyocyte apoptosis. In vitro, we examined the phenotype of IL ‐37 plus TnI–conditioned DC s of male C57 BL /6 mice and their capacity to influence the number of regulatory T cells. Our results revealed that IL ‐37 plus TnI–conditioned DC s obtained the characteristics of tolerogenic DCs ( tDC s) and expanded the number of regulatory T cells when co‐cultured with splenic CD 4 + T cells. Interestingly, we also found that adoptive transfer of these antigen‐loaded tDC s markedly increased the number of regulatory T cells in the spleen, attenuated the infiltration of inflammatory cells in the infarct hearts, decreased myocardial fibrosis, and improved cardiac function. Conclusions: Our results reveal a beneficial role of IL ‐37 or tDC s treated with IL ‐37 plus TnI in post‐ MI remodeling that is possibly mediated by reestablishing a tolerogenic immune response, indicating that IL ‐37 or adoptive transfer of IL ‐37 plus TnI–treated tDC s may be a novel therapeutic strategy for ventricular remodeling after MI.
Our previous study indicated that interleukin (IL)-37 is involved in atherosclerosis. In the present study, Anterior tibial arteries were collected from diabetes patients and controls. A histopathological analysis showed that IL-37 was over-expressed in human atherosclerotic plaques. Many types of cells including macrophages, vascular smooth muscle cells (VSMCs), endothelial cells and T lymphocyte expressed IL-37 in human atherosclerotic plaques. ApoE−/− mice were divided into a control group and a recombinant human IL-37-treated group. The IL-37 treatment resulted in a significant decrease in macrophages and CD4+ T lymphocytes and a substantial increase in VSMCs and collagen in atherosclerotic plaques, resulting in a reduction in atherosclerotic plaque size. Furthermore, the IL-37 treatment modulated the CD4+ T lymphocyte activity, including a decrease in T helper cell type 1 (Th1) and Th17 cells and an increase in regulatory T (Treg) cells, and inhibited the maturity of dendritic cells both in vivo and in vitro. In addition, treatment with anti-IL-10 receptor monoclonal antibody abrogated the anti-atherosclerotic effects of IL-37. These data suggest that exogenous IL-37 ameliorates atherosclerosis via inducing the Treg response. IL-37 may be a novel therapeutic to prevent and treat atherosclerotic disease.
Excessive immune‐mediated inflammatory reaction plays a deleterious role in ventricular remodelling after myocardial infarction (MI). Interleukin (IL)‐38 is a newly characterized cytokine of the IL‐1 family and has been reported to exert a protective effect in some autoimmune diseases. However, its role in cardiac remodelling post‐MI remains unknown. In this study, we found that the expression of IL‐38 was increased in infarcted heart after MI induced in C57BL/6 mice by permanent ligation of the left anterior descending artery. In addition, our data showed that ventricular remodelling after MI was significantly ameliorated after recombinant IL‐38 injection in mice. This amelioration was demonstrated by better cardiac function, restricted inflammatory response, attenuated myocardial injury and decreased myocardial fibrosis. Our results in vitro revealed that IL‐38 affects the phenotype of dendritic cells (DCs) and IL‐38 plus troponin I (TNI)‐treated tolerogenic DCs dampened adaptive immune response when co‐cultured with CD4+T cells. In conclusion, IL‐38 plays a protective effect in ventricular remodelling post‐MI, one possibility by influencing DCs to attenuate inflammatory response. Therefore, targeting IL‐38 may hold a new therapeutic potential in treating MI.
Objective. Recent studies suggest that IL‐38 is associated with autoimmune diseases. Furthermore, IL‐38 is expressed in human atheromatous plaque. However, the plasma levels of IL‐38 in patients with ST‐segment elevation myocardial infarction (STEMI) have not yet to be investigated. Methods. On admission, at 24 h, at 48 h, and at 7 days, plasma IL‐38, C‐reactive protein (CRP), cardiac troponin I (cTNI), and N‐terminal of the prohormone brain natriuretic peptide (NT‐proBNP) levels were measured and IL‐38 gene in peripheral blood mononuclear cells (PBMCs) was detected in STEMI patients. Results. The results showed that plasma IL‐38 levels and IL‐38 gene expression in PBMCs were significantly increased in STEMI patients compared with control group and were time dependent, peaked at 24 h. In addition, plasma IL‐38 levels were dramatically reduced in patients with reperfusion treatment compared with control group. Similar results were also demonstrated with CRP, cTNI, and NT‐proBNP levels. Furthermore, IL‐38 levels were found to be positively correlated with CRP, cTNI, and NT‐proBNP and be weakly negatively correlated with left ventricular ejection fraction (LVEF) in STEMI patients. Conclusions. The results indicate that circulating IL‐38 is a potentially novel biomarker for patients with STEMI and IL‐38 might be a new target for MI study.